Affinage

CLDN1

Claudin-1 · UniProt O95832

Length
211 aa
Mass
22.7 kDa
Annotated
2026-06-09
57 papers in source corpus 29 papers cited in narrative 29 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CLDN1 is a tetraspan tight junction transmembrane protein that establishes paracellular barrier function in epithelia and contributes to epidermal differentiation (PMID:9931503, PMID:11920682, PMID:38711223). Re-expression in claudin-negative cells localizes CLDN1 to cell-cell contacts and restores tight junction gate function independently of occludin, with the extracellular loop mediating junction assembly (PMID:11920682, PMID:31381894). Correct membrane targeting requires proper folding: the p.Arg81His missense variant causes mislocalization and distorted tight junction ultrastructure in keratinocytes (PMID:35920354, PMID:37814412), and CRISPR knockout in keratinocytes impairs barrier function, stratification, and filaggrin/cytokeratin-10 expression (PMID:38711223). CLDN1 transcription is governed by a defined regulatory network in which SP1 acts as a direct activator and is antagonized by BHLHE40, which sequesters SP1 from the promoter, by STAT3, which binds and represses the promoter downstream of IL-33/ERK signaling, and by EZH2-deposited H3K27me3 at the transcription start site (PMID:29534857, PMID:29704436, PMID:34789399); positive inputs include c-Fos recruited by the lncRNA WAKMAR2 (PMID:36461623). Beyond its junctional role, CLDN1 functions as a context-dependent regulator of invasion and cell survival: it drives epithelial-mesenchymal transition through interaction with SNAI1 and activation of Notch signaling (PMID:27974683, PMID:28316062), directly binds MMP14 to promote migration and inflammation (PMID:37964516), suppresses lung adenocarcinoma metastasis via a CLDN1-EPHB6-ERK1/2-SLUG feedback axis (PMID:32754286), and promotes chemoresistance by activating autophagy through ULK1 and AMPK/STAT1/ULK1 signaling (PMID:28614291, PMID:31498437).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 1999 Medium

    Established the molecular identity of CLDN1 as a claudin-family tight junction transmembrane protein, framing all subsequent functional work on barrier and polarity.

    Evidence cDNA cloning and sequence analysis of SEMP1/CLDN1

    PMID:9931503

    Open questions at the time
    • No functional reconstitution in the cloning study
    • Tissue distribution and partner proteins not defined
  2. 2002 High

    Resolved whether CLDN1 alone is sufficient for tight junction gate function, showing it restores paracellular barrier independently of occludin.

    Evidence Retroviral re-expression in claudin-negative breast cancer cells with localization and dextran flux assays

    PMID:11920682

    Open questions at the time
    • Molecular basis of selective permeability not addressed
    • Did not define which extracellular determinants mediate sealing
  3. 2004 High

    Linked CLDN1 membrane localization to apoptosis in 3D culture, indicating its barrier role has consequences for nutrient access and cell survival.

    Evidence Comparison of membrane vs cytosolic CLDN1 in 2D and 3D spheroid breast cancer cultures

    PMID:14648703

    Open questions at the time
    • Death-triggering signal mechanistically undefined
    • Generalizability beyond breast spheroids unknown
  4. 2016 Medium

    Connected CLDN1 to EMT and invasion through SNAI1 interaction and Notch activation, establishing a non-junctional pro-invasive function.

    Evidence Overexpression/knockdown with EMT markers, SNAI1 Co-IP, Notch rescue with Jagged-1, xenografts in cervical and bronchial cells

    PMID:27974683 PMID:28316062

    Open questions at the time
    • Direct binding interface with SNAI1 not mapped
    • Whether junctional vs cytosolic CLDN1 drives EMT unresolved
  5. 2017 Medium

    Identified autophagy activation via ULK1 as a route by which CLDN1 confers chemoresistance, expanding its role into cell survival signaling.

    Evidence CLDN1 manipulation with ULK1 phosphorylation analysis and autophagosome imaging in NSCLC under cisplatin

    PMID:28614291

    Open questions at the time
    • Mechanism coupling CLDN1 to ULK1 phosphorylation unknown
    • Direct vs indirect link not established
  6. 2018 High

    Defined the core transcriptional control of CLDN1, with SP1 as direct activator antagonized by BHLHE40 and by STAT3 downstream of IL-33/ERK.

    Evidence Promoter mapping, deletion mutants, BHLHE40-SP1 Co-IP, EMSA for STAT3 binding, and barrier assays in keratinocytes

    PMID:29534857 PMID:29704436

    Open questions at the time
    • Combinatorial logic among regulators not modeled
    • Tissue-specific selection of activators vs repressors unclear
  7. 2019 High

    Demonstrated context-dependent CLDN1 functions: metastasis suppression via an EPHB6-ERK1/2-SLUG axis, autophagy-driven progression via AMPK/STAT1/ULK1, and an extracellular-loop role in TJ assembly.

    Evidence Co-IP, ChIP, methylation assays, peptide TJ-disruption experiments, and xenograft models across lung and esophageal systems

    PMID:31381894 PMID:31498437 PMID:32754286

    Open questions at the time
    • What dictates pro- vs anti-metastatic output not defined
    • Nuclear CLDN1 distribution in ESCC mechanistically unexplained
  8. 2021 High

    Showed CLDN1 transcription is epigenetically repressed by EZH2/H3K27me3 and that CLDN1 supports cell survival via BIRC3, deepening regulatory and pro-survival mechanisms.

    Evidence ChIP-qPCR with EZH2 inhibitor rescue in vivo and BIRC3 rescue of CLDN1-knockdown apoptosis in trophoblasts

    PMID:33784242 PMID:34789399

    Open questions at the time
    • How EZH2 is recruited to the CLDN1 TSS not defined
    • Link between CLDN1 and BIRC3 regulation indirect
  9. 2022 Medium

    Established that proper folding underlies CLDN1 membrane targeting and that lncRNA WAKMAR2/c-Fos positively drives CLDN1 transcription to maintain barrier integrity.

    Evidence p.Arg81His variant cell modeling with immunofluorescence; RNA pull-down, promoter reporter, and ChIRP-seq for WAKMAR2

    PMID:35920354 PMID:36461623

    Open questions at the time
    • Disease mechanism of the variant at organism level not detailed here
    • Conditions selecting WAKMAR2/c-Fos activation unclear
  10. 2023 High

    Identified posttranscriptional and physical-partner control of CLDN1 (LIN28B mRNA binding, MMP14 direct interaction) and multiple upstream pathways (WNT7A/AKT, PI3K/AKT, MAPKp38/Wnt) governing CLDN1 in invasion, survival, and chemoresistance.

    Evidence RNA immunoprecipitation, Co-IP, pharmacological epistasis, phosphoproteomics, and in vivo metastasis/chemotherapy models across CRC, OSCC, ASMC, and trophoblast systems

    PMID:37041570 PMID:37277581 PMID:37318881 PMID:37523840 PMID:37541622 PMID:37814412 PMID:37964516

    Open questions at the time
    • Whether AKT acts on CLDN1 transcription or stability not separated
    • MMP14 and PMP22 binding interfaces unmapped
  11. 2024 High

    Provided clean loss-of-function evidence that CLDN1 is required for both barrier function and epidermal stratification, and placed it downstream of PDGFRβ signaling in adhesion biology.

    Evidence CRISPR/Cas9 keratinocyte knockout with organotypic and differentiation analyses; pathway analysis in a tendon adhesion model

    PMID:38699245 PMID:38711223

    Open questions at the time
    • How CLDN1 loss reprograms differentiation gene expression unknown
    • PDGFRβ-to-CLDN1 link is correlative
  12. 2025 Medium

    Unbiased screening identified CLDN1 as a mediator of drug sensitivity and reported a new physical partner, extending its functional repertoire.

    Evidence Genome-wide CRISPR knockout screen for berberine sensitivity in A549; ALFA-tag Co-IP/mass spectrometry identifying PMP22 in MDCKII cells (preprint)

    PMID:41383979 PMID:bio_10.1101_2025.09.03.673966

    Open questions at the time
    • Mechanism of berberine resistance via CLDN1 undefined
    • PMP22 interaction lacks functional validation and reciprocal confirmation
  13. 2026 Medium

    Linked extracellular matrix signaling to CLDN1 regulation, showing HM-HA via CD44 and HYAL1-dependent HA turnover control CLDN1 levels and barrier function.

    Evidence HM-HA treatment with CD44 and HYAL1 siRNA knockdown and barrier readouts in keratinocytes

    PMID:41881410

    Open questions at the time
    • Signaling cascade from CD44 to CLDN1 transcription not mapped
    • In vivo relevance to skin barrier disease unaddressed

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved what molecular switch determines whether CLDN1 acts as a barrier-sealing junctional protein versus a pro-invasive/pro-survival signaling effector, and how its subcellular distribution (membrane vs cytosolic/nuclear) is controlled to select these outputs.
  • No structural model of CLDN1 in distinct signaling complexes
  • Determinants of nuclear/cytosolic relocalization unknown
  • Context-dependence across tissues not mechanistically unified

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0005198 structural molecule activity 4 GO:0098631 cell adhesion mediator activity 2
Localization
GO:0005886 plasma membrane 4 GO:0005634 nucleus 1
Pathway
R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1500931 Cell-Cell communication 3 R-HSA-9612973 Autophagy 2
Partners
EPHB6LIN28BMMP14PMP22SNAI1SP1
Complex memberships
tight junction

Evidence

Reading pass · 29 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 CLDN1 (previously called SEMP1) encodes a protein with 91% identity to mouse claudin-1, a tight junction (TJ)-associated transmembrane protein, placing it in the epithelial membrane protein (EMP) superfamily with roles in cell polarity and paracellular permeability. cDNA cloning, differential display of mRNA, amino acid sequence analysis Gene Medium 9931503
2002 Re-expression of CLDN1 in CLDN1-negative breast cancer cells (MDA-MB-361 and MDA-MB-435) results in plasma membrane localization at cell-cell contact sites and inhibition of paracellular flux, even in the absence of occludin, demonstrating that CLDN1 alone is sufficient for tight junction gate function. Retroviral transduction, immunofluorescence, quantitative RT-PCR, paracellular dextran flux assay, Western blot Journal of cellular physiology High 11920682
2004 CLDN1 membrane localization in breast tumor spheroids (3D culture) induces apoptosis; cytosolic/heterogeneous CLDN1 distribution correlates with reduced apoptosis, indicating that membrane-targeted CLDN1 restricts nutrient/growth factor supply and triggers cell death in 3D but not 2D culture. Retroviral transduction, FACS sorting, apoptosis assays, immunofluorescence, paracellular flux measurement in 2D and 3D spheroid cultures International journal of cancer High 14648703
2016 CLDN1 overexpression in cervical cancer cells promotes invasion and metastasis by inducing epithelial-mesenchymal transition (EMT) through interaction with SNAI1, leading to decreased E-cadherin and increased vimentin expression. Overexpression in SiHa cells, invasion/migration assays, Western blot for EMT markers, xenograft mouse model, co-immunoprecipitation/interaction assay with SNAI1 Oncotarget Medium 27974683
2016 CLDN1 promotes TGF-β1-induced migration and EMT in bronchial epithelial cells via the Notch signaling pathway; CLDN1 knockdown reduces NICD and Hes-1 levels and abrogates TGF-β1-induced EMT, while Notch activator Jagged-1 reverses the protective effect of CLDN1 silencing. siRNA knockdown, Western blot, qRT-PCR, Transwell migration/invasion assays, Notch pathway rescue with Jagged-1 Molecular and cellular biochemistry Medium 28316062
2016 Nm23H1 regulates CLDN1 expression via the AKT signaling pathway in esophageal squamous cell carcinoma: Nm23H1 knockdown increases AKT phosphorylation and decreases CLDN1 expression, enhancing invasion; AKT inhibitor MK2206 restores CLDN1 expression in Nm23H1-depleted cells. siRNA knockdown, overexpression, Western blot for pAKT and CLDN1, invasion assays, AKT inhibitor treatment, immunofluorescence Oncogenesis Medium 27376780
2017 CLDN1 promotes cisplatin drug resistance in NSCLC by activating autophagy through upregulation of ULK1 phosphorylation. Western blot, CCK-8 proliferation assay, Transwell assay, confocal microscopy for autophagosomes, CLDN1 knockdown/overexpression Medical science monitor Medium 28614291
2017 TMPRSS4 upregulates CLDN1 expression via ERK1/2 signaling in hepatocellular carcinoma, thereby promoting cancer stem cell (CSC) traits including tumorsphere formation. Overexpression and knockdown studies, Western blot, ERK1/2 pathway analysis, tumorsphere assay Biochemical and biophysical research communications Low 28651932
2018 IL-33 downregulates CLDN1 expression in keratinocytes via the ERK/STAT3 signaling pathway; STAT3 directly binds the CLDN1 promoter and suppresses transcription, impairing epithelial barrier function. Western blot, real-time PCR, immunofluorescence, MAPK inhibitors, siRNA, TEER and FITC-dextran flux assays, EMSA for STAT3 promoter binding Journal of dermatological science High 29534857
2018 BHLHE40 suppresses CLDN1 transcription not by directly binding E-box motifs, but by interacting with SP1 and preventing SP1 from binding a specific motif (-233 to -61 bp upstream of the TSS) in the CLDN1 promoter; SP1 is identified as a major direct transcriptional activator of CLDN1. Reporter/luciferase assays, siRNA knockdown of SP1, co-immunoprecipitation, deletion mutant analysis, invasion assays Molecular carcinogenesis High 29704436
2019 CLDN1 suppresses lung adenocarcinoma metastasis via a feedback loop involving the CLDN1-EPHB6-ERK1/2-SLUG axis: CLDN1 upregulates and activates EPHB6, which suppresses ERK1/2 signaling; DNA hypermethylation of the CLDN1 promoter abrogates SLUG-mediated suppression of CLDN1 in high-metastatic cells. Immunoblots, immunoprecipitation, methylation-specific PCR, pyrosequencing, chromatin immunoprecipitation, reporter assay, sphere/aldefluor/flow cytometry assays, migration assay, xenograft Theranostics High 32754286
2019 Peptides derived from the first extracellular loop of CLDN1 transiently disrupt tight junctions in human lung epithelial cells and delay TJ formation in primary human keratinocytes, demonstrating that the extracellular loop mediates TJ assembly/integrity. Peptide design based on CLDN1 extracellular loop, TEER measurement, permeability assays, in vivo epicutaneous vaccine model Journal of Investigative Dermatology Medium 31381894
2019 CLDN1 promotes proliferation and metastasis of esophageal squamous cell carcinoma by triggering autophagy through the AMPK/STAT1/ULK1 signaling pathway; CLDN1 is aberrantly distributed to the nucleus in ESCC tumor cells. CLDN1 knockdown/overexpression, Western blot, in vitro and in vivo proliferation/metastasis assays, pathway inhibition Journal of cellular physiology Medium 31498437
2021 EZH2-mediated H3K27me3 suppresses CLDN1 transcription by accumulating at the CLDN1 TSS region, causing epithelial barrier dysfunction; EZH2 inhibition with GSK126 restores CLDN1 expression and barrier function in vivo. ChIP-qPCR, Western blot, TEER, FITC-dextran flux assay, EZH2 forced expression, in vivo rat EGDA model with EZH2 inhibitor Digestive and liver disease High 34789399
2021 CLDN1 regulates trophoblast cell survival: knockdown inhibits proliferation and induces apoptosis by decreasing BIRC3 expression and increasing cleaved PARP; BIRC3 overexpression rescues the apoptotic phenotype caused by CLDN1 knockdown. siRNA knockdown, overexpression, RNA-seq, Western blot, proliferation assay, apoptosis assay, BIRC3 rescue experiment Reproduction Medium 33784242
2022 A missense variant in CLDN1 (p.Arg81His) causes decreased CLDN1 expression and mislocalization of the protein in keratinocytes, with 3D protein modeling predicting deleterious conformational changes at Arg81, demonstrating that proper protein folding is required for correct membrane targeting. Whole exome sequencing, Sanger sequencing, 3D protein modeling, Western blot, immunofluorescence confocal microscopy, HaCaT transfection with mutant vs wildtype CLDN1 American journal of medical genetics. Part A Medium 35920354
2022 LncRNA WAKMAR2 directly binds c-Fos protein and recruits it to the CLDN1 promoter to enhance CLDN1 transcription, thereby maintaining keratinocyte barrier function; loss of WAKMAR2 reduces CLDN1 expression and barrier integrity. RNA pull-down, promoter-reporter assay, chromatin isolation by RNA purification-sequencing (ChIRP-seq), AP-1 inhibitor treatment, in vivo UV-irradiation mouse model Contact dermatitis High 36461623
2023 LIN28B directly binds and posttranscriptionally regulates CLDN1 mRNA (shown by RNA immunoprecipitation), promoting collective invasion, cell migration, and metastatic liver tumor formation; NOTCH3 is identified as a downstream effector of the LIN28B/CLDN1 axis. LIN28B knockdown/overexpression, RNA immunoprecipitation, in vitro invasion/migration assays, murine metastatic CRC model, bulk RNA sequencing, NOTCH3 genetic/pharmacological manipulation JCI insight High 37318881
2023 CLDN1 promotes airway smooth muscle cell (ASMC) proliferation, migration, invasion, and inflammation by directly interacting with MMP14; CLDN1 positively regulates MMP14 expression, and MMP14 overexpression reverses the inhibitory effects of CLDN1 silencing. Co-immunoprecipitation, protein-protein interaction assay, CCK-8, EdU assay, Transwell assay, ELISA for inflammatory factors, CLDN1 knockdown/overexpression Autoimmunity Medium 37964516
2023 CLDN1 knockdown suppresses trophoblast invasion, migration, and endovascular trophoblast (enEVT) differentiation, decreasing VIM, SNAIL, IL1B, and PECAM1 expression; CLDN1 overexpression promotes these processes, placing CLDN1 upstream of EMT/invasion markers in trophoblast biology. siRNA knockdown, overexpression, invasion/migration/tube formation assays, Western blot, qRT-PCR for enEVT markers, EOPE mouse model Placenta Medium 37523840
2023 CAF-derived WNT7A downregulates CLDN1 expression in OSCC cells via AKT signaling; AKT activation (SC79) reduces CLDN1, while AKT inhibitor (MK2206) restores CLDN1 and suppresses cancer cell migration, placing CLDN1 downstream of the WNT7A/AKT axis. Transwell coculture assay, microarray, WNT7A knockdown, phosphokinase array, AKT inhibitor/agonist treatment, CLDN1 knockdown, migration/invasion assays Laboratory investigation Medium 37541622
2023 CLDN1 upregulation induced by oxaliplatin chemotherapy is mediated at least in part by activation of the MAPKp38/GSK3β/Wnt/β-catenin pathway, and this CLDN1 overexpression confers resistance to apoptosis in CRC cells. Flow cytometry, immunofluorescence, Western blot, phosphoproteome analysis, proximity ligation assay, luciferase reporter assay, RNAseq, xenograft model Cell & bioscience Medium 37041570
2023 CLDN1 p.Arg81His variant causes distorted tight junction ultrastructure in patient skin as visualized by transmission electron microscopy, confirming that Arg81 is required for proper TJ architecture. Transmission electron microscopy of patient skin, haplotype analysis, immunofluorescence Clinical genetics Medium 37814412
2023 SEMP1/CLDN1 overexpression in trophoblast cells promotes proliferation, migration, invasion, and VEGFA secretion (facilitating endothelial tube formation) via PI3K/AKT signaling; PI3K inhibitor LY294002 blocks these effects. Overexpression and knockdown, cell proliferation/migration/invasion assays, VEGFA ELISA, endothelial tube formation assay, LY294002 pharmacological inhibition Molecular biotechnology Medium 37277581
2024 CLDN1 knockout keratinocytes (CRISPR/Cas9) show significantly reduced barrier function in monolayer and organotypic cultures, decreased filaggrin and cytokeratin-10 expression, diminished stratification, reduced stratum granulosum formation, and increased basal layer proliferation, establishing CLDN1 as required for both barrier function and proper epidermal stratification. CRISPR/Cas9 knockout, TEER measurement, organotypic culture, gene expression analysis, immunofluorescence, morphological analysis Experimental dermatology High 38711223
2024 Imatinib blocks peritendon adhesion formation by inhibiting the PDGFRβ/ERK/STAT3/CLDN1 pathway, placing CLDN1 as a downstream effector of PDGFRβ signaling in fibroblast/adhesion biology. In vivo tendon adhesion model, drug treatment, Western blot, pathway inhibition analysis Bioactive materials Low 38699245
2025 Genome-wide CRISPR/Cas9 knockout screening identified CLDN1 as a mediator of berberine sensitivity in lung cancer A549 cells; CLDN1 knockout markedly increased sensitivity to berberine, leading to enhanced G1-phase arrest and reduced proliferation, establishing CLDN1 as promoting cellular resistance to berberine. Genome-wide CRISPR/Cas9 knockout screening, functional validation (cell cycle analysis, proliferation assay) Oncology letters Medium 41383979
2025 CLDN1 directly interacts with PMP22 (peripheral myelin protein 22) in MDCKII epithelial cells, identified as a co-immunoprecipitation/mass spectrometry interactor in a cell-type-specific manner. Co-immunoprecipitation with ALFA-tag/nanobody, mass spectrometry, cross-context validation in multiple cell types bioRxiv (preprint)preprint Low bio_10.1101_2025.09.03.673966
2026 High-molecular-weight hyaluronan (HM-HA) decreases CLDN1 mRNA and protein expression in keratinocytes via the CD44 receptor; knockdown of CD44 suppresses HM-HA-induced CLDN1 downregulation. Additionally, knockdown of HYAL1 (the main HA-degrading enzyme) decreases CLDN1 expression, suggesting HYAL1-mediated HA degradation is required to maintain CLDN1 levels and TJ barrier function. HM-HA treatment, siRNA knockdown of CD44 and HYAL1, HA-degrading activity assay, Western blot, mRNA expression analysis Archives of biochemistry and biophysics Medium 41881410

Source papers

Stage 0 corpus · 57 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS letters 111 23523916
2004 Reexpression of the TJ protein CLDN1 induces apoptosis in breast tumor spheroids. International journal of cancer 102 14648703
1999 SEMP1, a senescence-associated cDNA isolated from human mammary epithelial cells, is a member of an epithelial membrane protein superfamily. Gene 76 9931503
2018 IL-33 down-regulates CLDN1 expression through the ERK/STAT3 pathway in keratinocytes. Journal of dermatological science 67 29534857
2002 Expression and targeting of the tight junction protein CLDN1 in CLDN1-negative human breast tumor cells. Journal of cellular physiology 59 11920682
2013 Up-regulation of CLDN1 in gastric cancer is correlated with reduced survival. BMC cancer 49 24321518
2017 miR-29a suppresses growth and migration of hepatocellular carcinoma by regulating CLDN1. Biochemical and biophysical research communications 48 28342862
2017 CLDN1 Increases Drug Resistance of Non-Small Cell Lung Cancer by Activating Autophagy via Up-Regulation of ULK1 Phosphorylation. Medical science monitor : international medical journal of experimental and clinical research 43 28614291
2020 Inhibition of miRNA-29a regulates intestinal barrier function in diarrhea-predominant irritable bowel syndrome by upregulating ZO-1 and CLDN1. Experimental and therapeutic medicine 41 33093893
2019 CLDN1 induces autophagy to promote proliferation and metastasis of esophageal squamous carcinoma through AMPK/STAT1/ULK1 signaling. Journal of cellular physiology 39 31498437
2016 CLDN1 expression in cervical cancer cells is related to tumor invasion and metastasis. Oncotarget 37 27974683
2016 MicroRNA-142-5p contributes to Hashimoto's thyroiditis by targeting CLDN1. Journal of translational medicine 34 27277258
2020 LncRNA XIST Promotes Migration and Invasion of Papillary Thyroid Cancer Cell by Modulating MiR-101-3p/CLDN1 Axis. Biochemical genetics 32 33057875
2020 DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression. Theranostics 26 32754286
2013 Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma. Journal of cardiothoracic surgery 24 23591077
2017 CLDN-1 promoted the epithelial to migration and mesenchymal transition (EMT) in human bronchial epithelial cells via Notch pathway. Molecular and cellular biochemistry 22 28316062
2016 Nm23H1 mediates tumor invasion in esophageal squamous cell carcinoma by regulation of CLDN1 through the AKT signaling. Oncogenesis 21 27376780
2009 Genetic variation in CLDN1 and susceptibility to hepatitis C virus infection. Journal of viral hepatitis 21 19674288
2014 Characterization of the small exported Plasmodium falciparum membrane protein SEMP1. PloS one 19 25062022
2023 LIN28B promotes cell invasion and colorectal cancer metastasis via CLDN1 and NOTCH3. JCI insight 18 37318881
2020 Upregulation of hsa-miR-31-3p induced by ultraviolet affects keratinocytes permeability barrier by targeting CLDN1. Biochemical and biophysical research communications 18 32907715
2024 Use of a pH-responsive imatinib mesylate sustained-release hydrogel for the treatment of tendon adhesion by inhibiting PDGFRβ/CLDN1 pathway. Bioactive materials 17 38699245
2023 Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells. Cell & bioscience 16 37041570
2013 Phospho-ΔNp63α regulates AQP3, ALOX12B, CASP14 and CLDN1 expression through transcription and microRNA modulation. FEBS letters 15 24070899
2021 CLDN1 regulates trophoblast apoptosis and proliferation in preeclampsia. Reproduction (Cambridge, England) 14 33784242
2019 Peptides Derived from the Tight Junction Protein CLDN1 Disrupt the Skin Barrier and Promote Responsiveness to an Epicutaneous Vaccine. The Journal of investigative dermatology 14 31381894
2018 Interaction with SP1, but not binding to the E-box motifs, is responsible for BHLHE40/DEC1-induced transcriptional suppression of CLDN1 and cell invasion in MCF-7 cells. Molecular carcinogenesis 14 29704436
2017 TMPRSS4 promotes cancer stem cell traits by regulating CLDN1 in hepatocellular carcinoma. Biochemical and biophysical research communications 14 28651932
2014 Polymorphisms in the CLDN1 and CLDN7 genes are related to differentiation and tumor stage in colon carcinoma. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 14 24479816
2014 Differential expression of claudin family members during osteoblast and osteoclast differentiation: Cldn-1 is a novel positive regulator of osteoblastogenesis. PloS one 13 25479235
2023 Role of Stromal Fibroblast-Induced WNT7A Associated with Cancer Cell Migration Through the AKT/CLDN1 Signaling Axis in Oral Squamous Cell Carcinoma. Laboratory investigation; a journal of technical methods and pathology 11 37541622
2022 CLDN1 Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy. Cancers 10 36291810
2024 CLDN1 knock out keratinocytes as a model to investigate multiple skin disorders. Experimental dermatology 9 38711223
2015 rs17501976 polymorphism of CLDN1 gene is associated with decreased risk of colorectal cancer in a Chinese population. International journal of clinical and experimental medicine 8 25785120
2022 Circ_0027446 induces CLDN1 expression to promote papillary thyroid cancer cell malignancy by binding to miR-129-5p. Pathology, research and practice 7 36058014
2021 Long non-coding RNA VPS9D1-AS1 promotes growth of colon adenocarcinoma by sponging miR-1301-3p and CLDN1. Human cell 7 34519940
2015 CD81 and CLDN1 polymorphisms and hepatitis C virus infection susceptibility: a case control study. Gene 7 25934191
2013 In silico analysis and validation of the proliferative potential of CLDN1 expression in gastric cancer. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 6 24579786
2022 Autosomal recessive congenital ichthyosis caused by a pathogenic missense variant in CLDN1. American journal of medical genetics. Part A 5 35920354
2022 LncRNA-WAKMAR2 regulates expression of CLDN1 to affect skin barrier through recruiting c-Fos. Contact dermatitis 5 36461623
2023 Upregulation of SEMP1 Contributes to Improving the Biological Functions of Trophoblast via the PI3K/AKT Pathway in Preeclampsia. Molecular biotechnology 3 37277581
2023 Downregulation of CLDN1 impairs trophoblast invasion and endovascular trophoblast differentiation in early-onset preeclampsia. Placenta 3 37523840
2023 CLDN1 silencing suppresses the proliferation and migration of airway smooth muscle cells by modulating MMP14. Autoimmunity 3 37964516
2021 EZH2-mediated suppression of CLDN1 leads to barrier dysfunction in PPI-refractory gastroesophageal reflux disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 3 34789399
2020 Single nucleotide variants c.-13G → C (rs17429833) and c.108C → T (rs72466472) in the CLDN1 gene and increased risk for familial colorectal cancer. Gene 3 33186612
2019 Polymorphisms in CLDN1 are associated with age and differentiation of triple-negative breast cancer patients. Bioscience reports 3 30910845
2025 circFOXK2 inhibits vascular permeability and angiogenesis in advanced lung adenocarcinoma via the miR-1275/CLDN1 axis. Biochemical and biophysical research communications 2 40850182
2024 Dual roles of BK Polyomavirus in promoting urothelial carcinoma progression via regulating CLDN1. Biomarker research 1 38245774
2023 CLDN1 Arg81His founder variant causes ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis (ILVASC) syndrome in Moroccan Jews. Clinical genetics 1 37814412
2008 Population genetics and comparative genetics of CLDN1, a gene involved in hepatitis C virus entry. Human heredity 1 19077439
2026 Role of HYAL1 on hyaluronan metabolism and the regulation of epidermal tight junction component CLDN1 in HaCaT cells. Archives of biochemistry and biophysics 0 41881410
2025 Neonatal ichthyosis-sclerosing cholangitis syndrome caused by a novel CLDN1 mutation: a case report and literature review. Clinical and experimental pediatrics 0 41035246
2025 PABPC3 drives ovarian cancer metastasis and drug sensitivity by downregulating CLDN1 expression. Cell death & disease 0 41249135
2025 Genome-wide CRISPR screening identifies CLDN1 as a central node in the anticancer mechanisms of berberine and as a therapeutic target in lung cancer. Oncology letters 0 41383979
2024 Expression of CLDN1 and EGFR in PTC. Discover oncology 0 39404969
2017 [Expression of CLDN1 and Its Nuclear Distribution in Esophageal Squamous Carcinoma]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 0 29260519
2005 Comparative mapping of human claudin-1 (CLDN1) in great apes. Cytogenetic and genome research 0 15545735

Missed literature

Know a paper Affinage missed for CLDN1? Flag it for the maintainers and the community.

No submissions yet.